Summary by Moomoo AI
Panbela Therapeutics, Inc. filed a prospectus supplement on May 15, 2024, to update and supplement information in its previous prospectus dated April 2, 2024, with details from its quarterly report filed with the SEC. The supplement pertains to the issuance of 8,750,000 shares of common stock underlying previously issued Class E and Class F common stock purchase warrants. The shares were initially registered on a registration statement and are quoted on the OTCQB under the symbol 'PBLA.' The last reported sales price of the common stock was $0.4408 per share as of May 14, 2024. The supplement, which includes the attached Quarterly Report, provides updated information and should be read in conjunction with the original prospectus. Panbela Therapeutics has incurred significant losses since inception and continues to face a high degree of risk, as detailed in the 'Risk Factors' section of the Prospectus and Quarterly Report. The company's ability to continue as a going concern is dependent on obtaining additional financing and achieving success in its development efforts and commercialization of its product candidates.
